ACN vs NAGE · P/E 24, rev $17.60B vs P/E 59, rev $61.3M
Accenture plc (ACN) versus Niagen Bioscience, Inc. (NAGE) — a side-by-side from cached financials, not a winner call.
Accenture plc (ACN) is a information technology services company listed on US.
Niagen Bioscience, Inc. (NAGE) is a biotechnology company listed on US.
Latest reported ACN revenue for 2025-08-31 was $17.60B. Net income was $1.41B. Revenue was down 0.7% from 2025-05-31 to 2025-08-31. ACN currently screens at market cap $186.16B and trailing P/E 23.8.
Latest reported NAGE revenue for 2026-06-30 was $61.3M. Net income was $7.3M. Revenue was up 94.6% from 2026-03-31 to 2026-06-30. NAGE currently screens at market cap $836.5M and trailing P/E 59.0.
ACN currently screens at market cap $186.16B and trailing P/E 23.8. NAGE currently screens at market cap $836.5M and trailing P/E 59.0.
Not investment advice. Open the ACN and NAGE stock pages for the full models.
Not investment advice.